Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
UK-390, 957 · 4 trials · 1 indication
| Name | Type | Description |
|---|---|---|
| UK-390,957 | DRUG | - |
Inclusion Criteria: * Subjects will have completed one of the phase 2 trials (A3871022/ A3871027/ A3871029) and will have met the diagnostic criteria for premature ejaculation as defined by DSM-IV Exclusion Criteria: * No drug related serious adverse events
UK-390,957 is an investigational small molecule being developed for men with premature ejaculation. It is in Phase 2 clinical development and has been studied in four completed trials with a total enrollment of 2,116 participants. The drug is not approved and remains under clinical investigation.
UK-390,957 is being developed by Pfizer, Inc. (NYSE: PFE). The company has sponsored four Phase 2 clinical trials of the drug, all of which have been completed. The trials enrolled men aged 18 years and older with premature ejaculation.
UK-390,957 is in Phase 2 clinical development. All four of its clinical trials are Phase 2 studies and have been completed. The drug is investigational and has not been approved by regulatory authorities. Its development status is based on the completed Phase 2 trials.
UK-390,957 has been studied in four completed Phase 2 trials: NCT00143117, NCT00219583, NCT00219609, and NCT00219635. These trials assessed the efficacy and safety of the drug in men with premature ejaculation, with enrollments ranging from 138 to 1,058 participants across multiple countries.
No, UK-390,957 is not the same as dapoxetine. UK-390,957 is a distinct investigational compound developed by Pfizer for premature ejaculation. Dapoxetine is a separate drug. The clinical trials for UK-390,957 are registered under their own NCT numbers and do not reference dapoxetine.